↓ Skip to main content
What is this page? Embed badge

Performability Has Its Price

Overview of attention for book
Cover of 'Performability Has Its Price'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Cooperation and QoS in Fast Packet Networks: The View from the Edge
  3. Altmetric Badge
    Chapter 2 How Many Parallel TCP Sessions to Open: A Pricing Perspective
  4. Altmetric Badge
    Chapter 3 Performance Modeling on the Interaction of ISPs
  5. Altmetric Badge
    Chapter 4 A Random Walk Model for Studying Allocation Patterns in Auction-Based Resource Allocation
  6. Altmetric Badge
    Chapter 5 A Simulation-Based Approach to Bidding Strategies for Network Resources in Competitive Wireless Networks
  7. Altmetric Badge
    Chapter 6 Charging in Peer-to-Peer Systems Based on a Token Accounting System
  8. Altmetric Badge
    Chapter 7 A Market-Managed Topology Formation Algorithm for Peer-to-Peer File Sharing Networks
  9. Altmetric Badge
    Chapter 8 Adapting a Captive Portal to Enable SMS-Based Micropayment for Wireless Internet Access
  10. Altmetric Badge
    Chapter 9 Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom
Attention for Chapter 9: Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom
Altmetric Badge

Mentioned by

policy
1 policy source

Readers on

mendeley
3 Mendeley
Summary Policy documents
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom
Chapter number 9
Book title
Performability Has its Price
Published in
International Journal of Technology Assessment in Health Care, February 2006
DOI 10.1007/11780502_9
Pubmed ID
16673685
Book ISBNs
978-3-54-035456-7, 978-3-54-035457-4
Authors

Colin Green, Jacqueline Dinnes, Andrea L. Takeda, Brian H. Cuthbertson

Abstract

The aim of this study was to assess the cost-effectiveness of drotrecogin alfa (activated) compared with best supportive care in a UK cohort of adult intensive-care patients with severe sepsis. A systematic review of evidence on the clinical- and cost-effectiveness of drotrecogin alfa (activated) was undertaken, and a decision-analytic model was developed to estimate the cost-effectiveness of treatment in the United Kingdom. Trial data from the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study have been synthesized with other data, including UK data on severe sepsis, to estimate the costs and consequences of treatment over time. For patients with severe sepsis and multiple organ dysfunction, the estimates of cost per life year and cost per quality-adjusted life year (QALY) are pounds 4931 and pounds 8228, respectively. For patients with severe sepsis alone, the cost per life-year and cost per QALY are pouhds 5495 and pounds 9161, respectively. Whereas the therapeutic cost for drotrecogin alfa (activated) appears high (at around pounds 5000 per patient) and the potential impact on the provider budget is considerable, drotrecogin alfa (activated) is clinically effective, represents a cost-effective use of resources, and is a significant advance in the treatment of severe sepsis in patients requiring intensive care.

View on publisher site
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 1 33%
Student > Doctoral Student 1 33%
Student > Master 1 33%
Readers by discipline Count As %
Computer Science 2 67%
Engineering 1 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2006.
All research outputs
#7,472,947
of 22,846,662 outputs
Outputs from International Journal of Technology Assessment in Health Care
#501
of 1,276 outputs
Outputs of similar age
#24,641
of 71,656 outputs
Outputs of similar age from International Journal of Technology Assessment in Health Care
#4
of 19 outputs
Altmetric has tracked 22,846,662 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,276 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 71,656 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.